Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Agenus Inc. - Common Stock
(NQ:
AGEN
)
2.905
-0.035 (-1.19%)
Streaming Delayed Price
Updated: 10:42 AM EST, Feb 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
59,050
Open
2.910
Bid (Size)
2.900 (4,800)
Ask (Size)
2.910 (200)
Prev. Close
2.940
Today's Range
2.840 - 2.940
52wk Range
1.380 - 7.340
Shares Outstanding
348,875,959
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Agenus (AGEN) Q2 2025 Earnings Call Transcript
↗
January 27, 2026
Agenus (AGEN) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
January 21, 2026
From
Agenus Inc.
Via
Business Wire
Performance
YTD
-10.1%
-10.1%
1 Month
-25.7%
-25.7%
3 Month
-31.0%
-31.0%
6 Month
-32.0%
-32.0%
1 Year
-10.1%
-10.1%
More News
Read More
Agenus to Host First 2026 Stakeholder Webcast
January 20, 2026
From
Agenus Inc.
Via
Business Wire
Earnings Scheduled For November 10, 2025
↗
November 10, 2025
Via
Benzinga
Thursday's session: top gainers and losers
↗
January 15, 2026
Via
Chartmill
Which stocks are moving on Thursday?
↗
January 15, 2026
Via
Chartmill
These stocks are gapping in today's session
↗
January 15, 2026
Via
Chartmill
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
January 15, 2026
From
Agenus Inc.
Via
Business Wire
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
January 12, 2026
From
Agenus Inc.
Via
Business Wire
Agenus (AGEN) Q3 2024 Earnings Call Transcript
↗
January 05, 2026
Via
The Motley Fool
Topics
Earnings
Agenus (AGEN) Q1 2025 Earnings Call Transcript
↗
January 05, 2026
Via
The Motley Fool
Topics
Earnings
Agenus (AGEN) Q4 2024 Earnings Call Transcript
↗
January 05, 2026
Via
The Motley Fool
Topics
Earnings
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
December 23, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
November 19, 2025
From
Agenus Inc.
Via
Business Wire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
From
Equity Insider
Via
GlobeNewswire
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
November 18, 2025
From
Agenus Inc.
Via
Business Wire
AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain
↗
November 10, 2025
Via
Chartmill
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
November 10, 2025
From
Agenus Inc.
Via
Business Wire
Insights Ahead: Agenus's Quarterly Earnings
↗
November 07, 2025
Via
Benzinga
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
Via
MarketMinute
Topics
Intellectual Property
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
November 05, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
October 17, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
October 16, 2025
From
Agenus Inc.
Via
Business Wire
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
September 09, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From
Agenus, Inc.
Via
Business Wire
Frequently Asked Questions
Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 2.905
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 02/09/26 10:42 AM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 1.01B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
